March 17, 2025 - 23:55
MINNEAPOLIS, March 17, 2025—DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for acute ischemic stroke and preeclampsia, has released its financial results for the year ending December 31, 2024. The company outlined its strategic initiatives and progress made over the past year, highlighting advancements in their clinical programs.
With a focus on addressing significant unmet medical needs, DiaMedica has made strides in its research efforts, particularly in the areas of acute ischemic stroke and preeclampsia. The company is committed to advancing its pipeline and believes that its innovative therapies have the potential to transform patient outcomes.
To further discuss these developments and the financial results, management will conduct a conference call on Tuesday, March 18, 2025, at 8:00 AM Eastern Time. This call will provide an opportunity for stakeholders to gain insights into the company’s future plans and ongoing projects.
